tiprankstipranks
Advertisement
Advertisement

HK:9926 Stock Latest News

Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
Company AnnouncementsAkeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
22h ago
9926
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
PremiumCompany Announcements
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
4d ago
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
PremiumCompany Announcements
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
7d ago
9926
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
PremiumCompany Announcements
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
21d ago
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
PremiumCompany Announcements
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
22d ago
Akeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsAkeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
23d ago
9926
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
Premium
Company Announcements
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
28d ago
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
Premium
Company Announcements
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
1M ago
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
PremiumRatings
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
RADX
SMMT
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
PremiumThe Fly
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
3M ago
SMMT
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
PremiumCompany Announcements
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
3M ago
Akeso Advances Dual-Antibody Cancer Trial, Keeping Oncology Pipeline in Focus
PremiumCompany AnnouncementsAkeso Advances Dual-Antibody Cancer Trial, Keeping Oncology Pipeline in Focus
4M ago
9926
Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline
Premium
Company Announcements
Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline
4M ago
9926
Akeso Schedules Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
Akeso Schedules Board Meeting to Approve 2025 Annual Results
4M ago
Akeso Advances AK112 Trial in Liver Cancer, Setting Up a New Catalyst for HK:9926
PremiumCompany Announcements
Akeso Advances AK112 Trial in Liver Cancer, Setting Up a New Catalyst for HK:9926
4M ago
9926
Akeso Completes Key Early-Stage Cancer Trial, Keeping Investor Focus on Pipeline Upside
PremiumCompany Announcements
Akeso Completes Key Early-Stage Cancer Trial, Keeping Investor Focus on Pipeline Upside
4M ago
9926
Akeso’s AK112 Lung Cancer Trial Reaches Completion: What Investors Should Watch Next
PremiumCompany Announcements
Akeso’s AK112 Lung Cancer Trial Reaches Completion: What Investors Should Watch Next
4M ago
9926
Akeso Moves AK139 Into Phase II, Targeting Growth in Seasonal Allergy Market
PremiumCompany Announcements
Akeso Moves AK139 Into Phase II, Targeting Growth in Seasonal Allergy Market
4M ago
9926
Akeso Advances New Asthma Biologic AK139 Into Phase II, Extending Its Respiratory Pipeline
PremiumCompany AnnouncementsAkeso Advances New Asthma Biologic AK139 Into Phase II, Extending Its Respiratory Pipeline
4M ago
9926
Akeso Advances AK104 Into Phase 3 Colon Cancer Trial, Signaling Long-Term Growth Potential
Premium
Company Announcements
Akeso Advances AK104 Into Phase 3 Colon Cancer Trial, Signaling Long-Term Growth Potential
4M ago
9926
Akeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
Premium
Company Announcements
Akeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >